ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

October 31, 2014

Children’s Oncology Group Study Shows Improved Care For Childhood Brain Tumors

October 31, 2008

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

June 27, 2014

In Brief: Donaldson, Wilson Lead ASTRO; Thomas To Hear Arguments In Cigarette Case; Doll, Peto Honored

November 8, 1991

Generic Paclitaxel Approval Withstands Court Challenge.

May 4, 2001

Cancer death rate dropping 1.1 percent a year, annual report finds.

October 7, 2005